Immunomic Therapeutics Archives

Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Published on : March 31, 2022March 31, 2022 Published by : BioBuzz Media

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held in New Orleans, Louisiana, from April 8-13. The posters to be presented at AACR are developed from the investigational nucleic acid platform, UNITE™ (UNiversal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma and Her2/Neu-LAMP DNA vaccine, both which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). This proprietary lysosomal targeting technology results in enhanced antigen presentation and a balanced T cell response.

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Published on : April 20, 2021April 20, 2021 Published by : BioBuzz Media

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

Taking a Job with an Emerging Biotech Presents Potential Life Changing Rewards

Published on : February 9, 2021February 9, 2021 Published by : Andy Eckert

Leaving the comforts of a big company with a calcified infrastructure, laser-focused job roles, well-established SOPs, deeper pockets, and excellent job security for the scramble and chaos of a younger company isn’t for everyone.

Six Biotechs to Watch in 2021

Published on : January 26, 2021January 28, 2021 Published by : Andy Eckert

2020 was an interesting year for the biotech industry and the BioHealth Capital Region as we adjusted to continue moving forward during the COVID-19 Pandemic. While the biggest stories in terms of dollars were related to the Coronavirus and funding to create a vaccine in record time, that didn’t stop other biotech companies from working hard to develop their research, science, and/or devices.

2020’s Top 10 Most Read News Stories from the BioHealth Capital Region

Published on : December 24, 2020December 22, 2020 Published by : Steven Surdez

2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.

End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region

Published on : December 24, 2020December 24, 2020 Published by : Steven Surdez

This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.

10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health

Published on : September 29, 2020December 21, 2020 Published by : Steven Surdez

The state of Maryland is the global epicenter of vaccine research and development. This has never been more evident than right now as scores of Maryland companies have risen to the global challenge of developing the first approved vaccine for SARS-CoV-2.